Atay Oguzhan sold $2.3M of BLLN

Atay Oguzhan (Chairman and CEO) sold 15,539 shares of BillionToOne, Inc. (BLLN) at $150.03 ($2.33M total) on 2026-08-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Aug 7, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale amount, date, and that it was executed under a pre-arranged Rule 10b5-1 plan; no other company-specific catalyst is provided.

02

Market read

Traders may note insider selling, but the 10b5-1 framing reduces the likelihood of a fundamental signal.

03

What to watch

The article provides only the sale details; it does not include any concurrent buy transactions, lockups, or changes in company fundamentals that would better explain trading impact.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-07, transaction dated 2026-08-05

Background

The article is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc. (BLLN).

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

BillionToOne Form 4 shows CEO/Chairman Atay Oguzhan sold 15,539 shares on 2026-08-05 under a 10b5-1 plan for about $2.33M.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment around insider selling.

Evidence & confidence

The filing is a Form 4 insider transaction with an explicitly stated 10b5-1 pre-arranged plan and no accompanying company guidance, deal, or regulatory event in the text.

Market effects

No sector-level implications disclosed; this is company-specific insider trading reporting.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan and the CEO still holds no shares after the sale, the market may overreact to a non-informational transaction.

Key entities

  • BillionToOne, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Atay Oguzhan

    Chairman and CEO who sold 15,539 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.